These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Deng R; Jin F; Prabhu S; Iyer S Expert Opin Drug Metab Toxicol; 2012 Feb; 8(2):141-60. PubMed ID: 22248267 [TBL] [Abstract][Full Text] [Related]
3. The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment. Lansita JA; Mounho-Zamora B Curr Pain Headache Rep; 2015; 19(2):2. PubMed ID: 25681157 [TBL] [Abstract][Full Text] [Related]
4. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology. Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research. Zhang Y; Doshi S; Zhu M Br J Clin Pharmacol; 2015 Nov; 80(5):957-64. PubMed ID: 25912961 [TBL] [Abstract][Full Text] [Related]
6. Drug interaction studies of therapeutic proteins or monoclonal antibodies. Mahmood I; Green MD J Clin Pharmacol; 2007 Dec; 47(12):1540-54. PubMed ID: 17962422 [TBL] [Abstract][Full Text] [Related]
7. [Biomarkers and pharmacokinetic-pharmacodynamic studies of immunosuppressive agents]. Paintaud G; Bénéton M; Watier H Therapie; 2004; 59(2):179-83. PubMed ID: 15359609 [TBL] [Abstract][Full Text] [Related]
8. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Zhou H; Davis HM Drug Discov Today; 2009 Sep; 14(17-18):891-8. PubMed ID: 19520183 [TBL] [Abstract][Full Text] [Related]
9. Frontiers in nonclinical drug development: biosimilars. Ryan AM Vet Pathol; 2015 Mar; 52(2):419-26. PubMed ID: 25161206 [TBL] [Abstract][Full Text] [Related]
10. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. Kamath AV; Iyer S Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773 [TBL] [Abstract][Full Text] [Related]
11. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates. Sauerborn M; van Dongen W BioDrugs; 2014 Aug; 28(4):383-91. PubMed ID: 24842227 [TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future. Vezina HE; Cotreau M; Han TH; Gupta M J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650 [TBL] [Abstract][Full Text] [Related]
15. Overview status of preclinical safety assessment for immunomodulatory biopharmaceuticals. Green JD; Black LE Hum Exp Toxicol; 2000 Apr; 19(4):208-12. PubMed ID: 10918509 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. Mould DR; Green B BioDrugs; 2010 Feb; 24(1):23-39. PubMed ID: 20055530 [TBL] [Abstract][Full Text] [Related]
18. Drug Development of Therapeutic Monoclonal Antibodies. Mould DR; Meibohm B BioDrugs; 2016 Aug; 30(4):275-93. PubMed ID: 27342605 [TBL] [Abstract][Full Text] [Related]
19. Strategies to address drug interaction potential for antibody-drug conjugates in clinical development. Lu D; Sahasranaman S; Zhang Y; Girish S Bioanalysis; 2013 May; 5(9):1115-30. PubMed ID: 23641700 [TBL] [Abstract][Full Text] [Related]